Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes

Hua Liu, Zhaohui Ye, Yonghak Kim, Saul Sharkis, Yoon Young Jang

Research output: Contribution to journalArticle

Abstract

Recent advances in induced pluripotent stem (iPS) cell research have significantly changed our perspective on regenerative medicine. Patient-specific iPS cells have been derived not only for disease modeling but also as sources for cell replacement therapy. However, there have been insufficient data to prove that iPS cells are functionally equivalent to human embryonic stem (hES) cells or are safer than hES cells. There are several important issues that need to be addressed, and foremost are the safety and efficacy of human iPS cells of different origins. Human iPS cells have been derived mostly from cells originating from mesoderm and in a few cases from ectoderm. So far, there has been no report of endoderm-derived human iPS cells, and this has prevented comprehensive comparative investigations of the quality of human iPS cells of different origins. Here we show for the first time reprogramming of human endoderm-derived cells (i.e., primary hepatocytes) to pluripotency. Hepatocyte-derived iPS cells appear indistinguishable from hES cells with respect to colony morphology, growth properties, expression of pluripotency-associated transcription factors and surface markers, and differentiation potential in embryoid body formation and teratoma assays. In addition, these cells are able to directly differentiate into definitive endoderm, hepatic progenitors, and mature hepatocytes. Conclusion: The technology to develop endoderm-derived human iPS cell lines, together with other established cell lines, will provide a foundation for elucidating the mechanisms of cellular reprogramming and for studying the safety and efficacy of differentially originated human iPS cells for cell therapy. For the study of liver disease pathogenesis, this technology also provides a potentially more amenable system for generating liver disease-specific iPS cells.

Original languageEnglish (US)
Pages (from-to)1810-1819
Number of pages10
JournalHepatology
Volume51
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Induced Pluripotent Stem Cells
Endoderm
Hepatocytes
Cell- and Tissue-Based Therapy
Liver Diseases
Technology
Embryoid Bodies
Safety
Stem Cell Research
Cell Line
Ectoderm
Regenerative Medicine
Differentiation Antigens
Teratoma
Mesoderm
Transcription Factors

ASJC Scopus subject areas

  • Hepatology

Cite this

Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. / Liu, Hua; Ye, Zhaohui; Kim, Yonghak; Sharkis, Saul; Jang, Yoon Young.

In: Hepatology, Vol. 51, No. 5, 05.2010, p. 1810-1819.

Research output: Contribution to journalArticle

Liu, Hua ; Ye, Zhaohui ; Kim, Yonghak ; Sharkis, Saul ; Jang, Yoon Young. / Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. In: Hepatology. 2010 ; Vol. 51, No. 5. pp. 1810-1819.
@article{5f04c7381389469b8882b2da80942205,
title = "Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes",
abstract = "Recent advances in induced pluripotent stem (iPS) cell research have significantly changed our perspective on regenerative medicine. Patient-specific iPS cells have been derived not only for disease modeling but also as sources for cell replacement therapy. However, there have been insufficient data to prove that iPS cells are functionally equivalent to human embryonic stem (hES) cells or are safer than hES cells. There are several important issues that need to be addressed, and foremost are the safety and efficacy of human iPS cells of different origins. Human iPS cells have been derived mostly from cells originating from mesoderm and in a few cases from ectoderm. So far, there has been no report of endoderm-derived human iPS cells, and this has prevented comprehensive comparative investigations of the quality of human iPS cells of different origins. Here we show for the first time reprogramming of human endoderm-derived cells (i.e., primary hepatocytes) to pluripotency. Hepatocyte-derived iPS cells appear indistinguishable from hES cells with respect to colony morphology, growth properties, expression of pluripotency-associated transcription factors and surface markers, and differentiation potential in embryoid body formation and teratoma assays. In addition, these cells are able to directly differentiate into definitive endoderm, hepatic progenitors, and mature hepatocytes. Conclusion: The technology to develop endoderm-derived human iPS cell lines, together with other established cell lines, will provide a foundation for elucidating the mechanisms of cellular reprogramming and for studying the safety and efficacy of differentially originated human iPS cells for cell therapy. For the study of liver disease pathogenesis, this technology also provides a potentially more amenable system for generating liver disease-specific iPS cells.",
author = "Hua Liu and Zhaohui Ye and Yonghak Kim and Saul Sharkis and Jang, {Yoon Young}",
year = "2010",
month = "5",
doi = "10.1002/hep.23626",
language = "English (US)",
volume = "51",
pages = "1810--1819",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes

AU - Liu, Hua

AU - Ye, Zhaohui

AU - Kim, Yonghak

AU - Sharkis, Saul

AU - Jang, Yoon Young

PY - 2010/5

Y1 - 2010/5

N2 - Recent advances in induced pluripotent stem (iPS) cell research have significantly changed our perspective on regenerative medicine. Patient-specific iPS cells have been derived not only for disease modeling but also as sources for cell replacement therapy. However, there have been insufficient data to prove that iPS cells are functionally equivalent to human embryonic stem (hES) cells or are safer than hES cells. There are several important issues that need to be addressed, and foremost are the safety and efficacy of human iPS cells of different origins. Human iPS cells have been derived mostly from cells originating from mesoderm and in a few cases from ectoderm. So far, there has been no report of endoderm-derived human iPS cells, and this has prevented comprehensive comparative investigations of the quality of human iPS cells of different origins. Here we show for the first time reprogramming of human endoderm-derived cells (i.e., primary hepatocytes) to pluripotency. Hepatocyte-derived iPS cells appear indistinguishable from hES cells with respect to colony morphology, growth properties, expression of pluripotency-associated transcription factors and surface markers, and differentiation potential in embryoid body formation and teratoma assays. In addition, these cells are able to directly differentiate into definitive endoderm, hepatic progenitors, and mature hepatocytes. Conclusion: The technology to develop endoderm-derived human iPS cell lines, together with other established cell lines, will provide a foundation for elucidating the mechanisms of cellular reprogramming and for studying the safety and efficacy of differentially originated human iPS cells for cell therapy. For the study of liver disease pathogenesis, this technology also provides a potentially more amenable system for generating liver disease-specific iPS cells.

AB - Recent advances in induced pluripotent stem (iPS) cell research have significantly changed our perspective on regenerative medicine. Patient-specific iPS cells have been derived not only for disease modeling but also as sources for cell replacement therapy. However, there have been insufficient data to prove that iPS cells are functionally equivalent to human embryonic stem (hES) cells or are safer than hES cells. There are several important issues that need to be addressed, and foremost are the safety and efficacy of human iPS cells of different origins. Human iPS cells have been derived mostly from cells originating from mesoderm and in a few cases from ectoderm. So far, there has been no report of endoderm-derived human iPS cells, and this has prevented comprehensive comparative investigations of the quality of human iPS cells of different origins. Here we show for the first time reprogramming of human endoderm-derived cells (i.e., primary hepatocytes) to pluripotency. Hepatocyte-derived iPS cells appear indistinguishable from hES cells with respect to colony morphology, growth properties, expression of pluripotency-associated transcription factors and surface markers, and differentiation potential in embryoid body formation and teratoma assays. In addition, these cells are able to directly differentiate into definitive endoderm, hepatic progenitors, and mature hepatocytes. Conclusion: The technology to develop endoderm-derived human iPS cell lines, together with other established cell lines, will provide a foundation for elucidating the mechanisms of cellular reprogramming and for studying the safety and efficacy of differentially originated human iPS cells for cell therapy. For the study of liver disease pathogenesis, this technology also provides a potentially more amenable system for generating liver disease-specific iPS cells.

UR - http://www.scopus.com/inward/record.url?scp=77951473757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951473757&partnerID=8YFLogxK

U2 - 10.1002/hep.23626

DO - 10.1002/hep.23626

M3 - Article

C2 - 20432258

AN - SCOPUS:77951473757

VL - 51

SP - 1810

EP - 1819

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -